Flow cytometric evaluation of T and B lymphocyte percentage in chronic kidney disease

Ayna, Tülay Kılıçaslan; Akman, Burcu; Koçyiğit, Aslı Özkızılcık; Güleç, Derya; Tuğmen, Cem; Soyöz, Mustafa

doi:10.5603/mrj.2017.0005

Cited by 1 publication

(1 citation statement)

References 8 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both T and B cells were numerically higher among healthy donors compared to CKD groups, with statistical significance in T cell subtype. 25 All-cause mortality among 104 hemodialysis patients was evaluated by Molina et al, 2018, they stated that a low total lymphocyte count (below the normal laboratory range) was found in 45.2% of the studied hemodialysis patients. The CD19+ B cell was the most frequent lymphopenias (57.7%) followed by CD3+ T cell (40.4%) and CD56+CD16+CD3− natural killer (8.7%).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of klotho expression on peripheral blood lymphocytes among hemodialysis patients and its possible contribution to their immuno-compromised status

Elmahalawy,

Farres

2024

EJI

View full text Add to dashboard Cite

Infection is the second most common cause of mortality among end-stage kidney disease (ESKD) patients. Uremic toxins are the main cause of impaired immune response among ESKD patients. Klotho gene, the anti-aging gene, encodes the transmembrane alpha klotho (αKL) protein which acts as an obligate coreceptor for fibroblast growth factor 23 (FGF23). Klotho protein may play a role in immune cell functions, particularly in anti-inflammatory response; however, its role is still incompletely understood. In the present study, we aimed to measure αKL protein expression on peripheral blood lymphocytes (PBLs) among hemodialysis (HD) patients, and we assumed that decreased αKL expression on PBLs may contribute to the impaired immunity among HD patients. This case-control study included 20 ESKD patients on regular hemodialysis for more than 3 months. Their ages ranged from 24 to 69 years. Patients with primary immunodeficiencies, those on systemic immunosuppressive drugs, those with ongoing infections or who had recently recovered from infections, and those with malignancies on active treatment were excluded. A control group of 20 normal subjects of comparable age and gender were also included. We compared αKL protein expression on PBLs by flow cytometry between both groups. Significant reductions in percentages of αKL protein expression on B lymphocytes (CD19), T lymphocytes (CD3), and natural killer cells (CD56) were observed among HD patients compared to controls. We also noticed a significant reduction in the percentages of natural killer cells among HD patients. The present study suggests that decreased αKL expression on PBLs may contribute to the immunocompromised status among HD patients, highlighting the importance of understanding the exact function of αKL protein on immune cells. This may offer a future diagnostic and therapeutic tool to improve the immune response among HD patients.

show abstract

Section: Discussionmentioning

confidence: 99%